Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Other Non-Current Liabilities (2022 - 2024)

Historic Other Non-Current Liabilities for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2024 value amounting to $18.8 million.

  • NewAmsterdam Pharma's Other Non-Current Liabilities changed N/A to $18.8 million in Q3 2024 from the same period last year, while for Sep 2024 it was $18.8 million, marking a year-over-year change of. This contributed to the annual value of $7.8 million for FY2023, which is 353.63% up from last year.
  • Latest data reveals that NewAmsterdam Pharma reported Other Non-Current Liabilities of $18.8 million as of Q3 2024.
  • Over the past 5 years, NewAmsterdam Pharma's Other Non-Current Liabilities peaked at $18.8 million during Q3 2024, and registered a low of $7.2 million during Q4 2022.
  • In the last 3 years, NewAmsterdam Pharma's Other Non-Current Liabilities had a median value of $10.8 million in 2023 and averaged $12.0 million.
  • In the last 5 years, NewAmsterdam Pharma's Other Non-Current Liabilities skyrocketed by 822.97% in 2023 and then skyrocketed by 6285.2% in 2024.
  • Quarter analysis of 3 years shows NewAmsterdam Pharma's Other Non-Current Liabilities stood at $7.2 million in 2022, then rose by 8.23% to $7.8 million in 2023, then soared by 141.5% to $18.8 million in 2024.
  • Its Other Non-Current Liabilities was $18.8 million in Q3 2024, compared to $13.4 million in Q2 2024 and $16.5 million in Q1 2024.